Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod in Facioscapulohumeral Muscular Dystrophy
NCT05397470Phase 3Terminated
- Sponsor
- Fulcrum Therapeutics
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Fulcrum Therapeutics. Started Jun 2022; status: terminated.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT05397470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397470.